Table 4 LysoPC a C20:4 varied with MELD Score and disease progression from CHB to HBV-associated cirrhosis and to HBV-associated HCC.
Variables | CHB | HBV-associated cirrhosis | HBV-associated HCC | |||
---|---|---|---|---|---|---|
MELD≤8.99 | MELD>8.99 | MELD≤8.99 | MELD>8.99 | MELD≤8.99 | MELD>8.99 | |
N | 109 | 27 | 29 | 75 | 30 | 65 |
Age(ys) | 40.00(32.00–51.00) | 45.00(35.50–58.00) | 55.00(50.00–62.00) | 57.00(48.50–64.50) | 56.00(47.00–64.50) | 56.00(47.00–61.00) |
BMI(kg/m2) | 23.66(22.03–24.91) | 23.67(21.76–24.28) | 23.51(20.58–25.71) | 23.44(21.16–25.14) | 22.07(19.36–23.71) | 22.32(19.82–24.22) |
Gender(F/M) | 45/64 | 6/21 | 15/14 | 28/47 | 7/23 | 7/58 |
lysoPC a C18:0(μmol/L) | 35.83(24.65–44.59) | 30.38(26.94–40.27) | 32.1(21.47–43.82) | 22.97(16.04–33.77)* | 30.66(25.39–36.05) | 17.76(14.31–25.86)*** |
lysoPC a C18:2(μmol/L)Δ | 24.06(19.85–29.05) | 20.47(14.09–28.31) | 22.46(17.47–29.85) | 18.22(12.49–24.97) | 20.31(16.81–26.36) | 13.25(9.87–19.22)** |
lysoPC a C20:3(μmol/L)Δ | 1.51(1.21–1.94) | 1.46(1.07–1.94) | 1.42(1.09–1.80) | 1.10(0.80–1.52)* | 1.46(0.98–1.68) | 0.89(0.72–1.20)*** |
lysoPC a C20:4(μmol/L)Δ | 4.91(3.61–6.25) | 3.92(3.22–5.68)* | 4.73(3.32–5.88) | 3.17(2.34–4.37)** | 3.86(2.76–5.37) | 2.78(2.02–3.76)** |
lysoPC a C24:0(μmol/L) | 0.43(0.26–0.55) | 0.35(0.25–0.69) | 0.39(0.16–0.54) | 0.29(0.20–0.41) | 0.24(0.15–0.42) | 0.29(0.19–0.41) |
PC ae C42:1(μmol/L) | 0.34(0.28–0.40) | 0.29(0.27–0.35)* | 0.30(0.22–0.38) | 0.29(0.20–0.36) | 0.26(0.21–0.30) | 0.26(0.20–0.33) |
AC C18:2(μmol/L)Δ | 0.09(0.04–0.13) | 0.10(0.07–0.13) | 0.13(0.06–0.15) | 0.15(0.09-0.20) | 0.09(0.07–0.15) | 0.11(0.07–0.16) |
AC C3-OH(μmol/L) | 0.18(0.14–0.22) | 0.18(0.14–0.21) | 0.18(0.12–0.22) | 0.14(0.12–0.18) | 0.17(0.14–0.22) | 0.16(0.12–0.22) |
SM C24:1(μmol/L) | 27.16(17.74–38.11) | 35.38(23.43–46.77) | 21.49(8.14–35.62) | 21.67(15.15–31.74) | 22.84(14.18–39.60) | 32.86(18.55–48.79) |